163705-72-4

Upstream product

• 108-86-1 bromobenzene 
• 67387-76-2 3-cyclopentyloxy-4-methoxybenzylaldehyde 
• 7429-90-5 aluminium 
• 137-43-9 Cyclopentyl bromide 
• 621-59-0 isovanillin 
• 100-58-3 phenylmagnesium bromide 

Downstream Products

• 162543-72-8 [3-(cyclopentyloxy)-4-methoxyphenyl]phenylmethanone 
• 190204-71-8 4-[2-(3-cyclopentyloxy-4-methoxyphenyl)-2-(phenyl)ethyl]pyridine 
• 162544-01-6 2-Cyclopentyloxy-1-methoxy-4-(1-phenyl-vinyl)-benzene 
• 468736-83-6 2-Cyclopentyloxy-4-((E)-1,2-diphenyl-vinyl)-1-methoxy-benzene 
• 190204-35-4 4-[(E)-2-(3-Cyclopentyloxy-4-methoxy-phenyl)-2-phenyl-vinyl]-pyridine 
• 162543-82-0 4-[(Z)-2-(3-Cyclopentyloxy-4-methoxy-phenyl)-2-phenyl-vinyl]-pyridine 
• 162543-81-9 (E)-2-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-phenyl-1-(4-pyridyl)ethene 

Relevant academic research and scientific papers

Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-asthmatics

A new series of catechol hydrazines was synthesized and their structure-activity relationship (SAR) was analyzed for developing an effective phosphodiesterase 4 (PDE4) inhibitor as an anti-asthmatic drug candidate. Among the (E)-Analogues tested using in

CDP840. A prototype of a novel class of orally active anti-inflammatory phosphodiesterase 4 inhibitors

The discovery, synthesis and biological activity of a series of triarylethane phosphodiesterase 4 inhibitors is described. Structure-activity relationship studies are presented for CDP840 (29), a potent, chiral, selective inhibitor of PDE 4 (IC50/su

Phenylpyridyl compounds for inhibiting phosphodiesterase IV and methods of using same

PCT No. PCT/US96/00519 Sec. 371 Date Nov. 13, 1997 Sec. 102(e) Date Nov. 13, 1997 PCT Filed Jan. 11, 1996 PCT Pub. No. WO96/21435 PCT Pub. Date Jul. 18, 1996Novel compounds which are effective PDE IV inhibitors are disclosed. The compounds possess improve

1,3-DIHYDRO-1-(PHENYLALKENYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDE IV AND CYTOKINE INHIBITING ACTIVITY

The present invention concerns the compounds of formula STR1 the N-oxide forms, the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof, wherein R. sup.1 and R. sup. 2 each independently are hydrogen; C

Asymmetric synthesis of CDP840 by Jacobsen epoxidation. An unusual syn selective reduction of an epoxide

An asymmetric synthesis of the PDE IV inhibitor, CDP840 (3) is reported. The absolute stereochemistry was controlled by a Jacobsen epoxidation of the Z triaryl olefin 8 (89% ee) or the E triaryl olefin 9 (48% ee). The disparate results in stereocontrol were interpreted in terms of the 'skewed side-on approach model' proposed by Jacobsen. LiBH4 · BH3 reduction of the epoxides was found to proceed with retention of configuration.

Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV

Rolipram-based PDE IV inhibitors containing phenyl- or benzyl-substituted moieties of the formula: STR1 wherein X1 and X2 may be the same or different and each is O or S; R1 is selected from the group consisting of hydroge